Rolofylline
136199-02-5CCCn1c(=O)c2[nH]c(C34C[C@@H]5CC3C[C@@H](C5)C4)nc2n(CCC)c1=OPJBFVWGQFLYWCB-QUYAXPHCSA-NRolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Danger
H370 (47.3%): Causes damage to organs [Danger Specific target organ toxicity, single exposure]
P260, P264, P270, P273, P308+P316, P319, P321, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 74 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Rolofylline is an adenosine A1-receptor antagonist. Plasma adenosine levels are elevated in patients with heart failure and adenosine A1 receptors in the kidney mediate vasoconstriction of afferent arterioles, reabsorption of sodium and water in proximal tubules, and tubuloglomerular feedback in the juxtaglomerular apparatus. Accordingly, inhibition of these receptors would be expected to increase renal blood flow and enhance diuresis. The effects of Rolofylline on renal function are consistent with those obtained with another adenosine A1-receptor antagonist in both experimental and human heart failure.
개요KW 3902 is an antagonist of the adenosine A1 receptor (Ki = 0.19 nM). It displays 890-fold selectivity for A1 receptors over A2A receptors and has no activity at A3 receptors. KW 3902 less potently inhibits human organic anion transporter 1 (OAT1; Ki = 7.82 μM). KW 3902 exhibits renal protective effects during hypoxemia in rabbits.
용도KW 3902 is an adenosine A1-receptor antagonist, which has recently been shown to alleviate axonopathy caused by human Tau ΔK280. KW 3902 can be considered for the development of a treatment towards hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
136199-02-5CHEMBL52333